Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present CytomX Therapeutics, Inc. (NASDAQ: CTMX).

Full DD Report for CTMX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CTMX)

CytomX up 6% premarket on CX-072 data
CytomX Therapeutics (NASDAQ: CTMX ) is up  6%  premarket on light volume on the heels of the release of ASCO abstracts on its Phase 1/2 PROCLAIM-072 study assessing PD-L1-targeting Probody therapeutic CX-072 in solid tumors. More news on: CytomX Therapeutics, Healthcare stock...
Source: SeekingAlpha
Date: May, 17 2018 08:15
CytomX Therapeutics Announces Presentations at 2018 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, t...
Source: GlobeNewswire
Date: May, 16 2018 17:05
CytomX beats by $0.05, misses on revenue
CytomX (NASDAQ: CTMX ): Q1 EPS of -$0.40 beats by $0.05 . More news on: CytomX Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 09 2018 16:14
CytomX Therapeutics Announces First Quarter 2018 Financial Results
- Initial clinical data from the Phase 1/2 CX-072 program to be reported at American Society of Clinical Oncology Annual Meeting - SOUTH SAN FRANCISCO, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical ...
Source: GlobeNewswire
Date: May, 09 2018 16:05
ImmunoGen: An Extremely Promising ADC Therapeutic Innovator
Choose clients as you would friends. - Charlie Munger ImmunoGen (NASDAQ: IMGN ) is a highly promising bioscience that is harnessing the power of ADC to deliver the next-generation cancer treatment. The company has an invaluable asset, ADC that, in and of itself, is licensed to other st...
Source: SeekingAlpha
Date: May, 09 2018 02:02
CytomX to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, ...
Source: GlobeNewswire
Date: May, 07 2018 16:00
CytomX Therapeutics to Announce First Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, plans to report first quarter 2018 financial results on Wedn...
Source: GlobeNewswire
Date: May, 01 2018 16:01
Report: Developing Opportunities within CytomX Therapeutics, Pegasystems, Greif, Belden, Payment Data, and KAR Auction Services - Future Expectations, Projections Moving into 2018
NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CytomX Therapeutics, Inc. (NASDAQ:CTMX), Pegasystems Inc. (NASDAQ:PEGA),...
Source: GlobeNewswire
Date: April, 26 2018 07:40
By The Numbers: Best Biotech Stocks
Investing in biotech stocks can be a double-edged sword. When positioned in the right biotech names, investors can be rewarded with massive gains. On the other hand, the losses are also substantial if you pick the wrong stocks in the sector. There is no infallible formula to picking winning ...
Source: SeekingAlpha
Date: April, 05 2018 06:47
Blog Exposure - Bellicum Reported Encouraging Interim Data in Pediatric AML Patients Treated with BPX-501
Stock Monitor: CytomX Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free research report on Bellicum Pharma, Inc. (NASDAQ: BLCM ). If you want access to this report all you need to do is sign up now by clickin...
Source: ACCESSWIRE IA
Date: March, 15 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1722.8522.4922.8922.40157,146
2018-08-1622.7722.8423.249922.25221,761
2018-08-1522.5322.6322.7922.00294,883
2018-08-1423.9122.5623.9522.55351,992
2018-08-1324.2923.9424.3823.62384,297

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-177,28017,32242.0275Short
2018-08-1610,14048,79820.7795Cover
2018-08-1523,03850,50145.6189Short
2018-08-1422,74144,20751.4421Short
2018-08-1328,00260,67046.1546Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CTMX.


About CytomX Therapeutics, Inc. (NASDAQ: CTMX)

Logo for CytomX Therapeutics, Inc. (NASDAQ: CTMX)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $897,323,312 - 05/15/2018
  • Issue and Outstanding: 38,611,158 - 03/05/2018

 


Recent Filings from (NASDAQ: CTMX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 26 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: March, 14 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 07 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: CTMX)

Daily Technical Chart for (NASDAQ: CTMX)


Stay tuned for daily updates and more on (NASDAQ: CTMX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CTMX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CTMX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CTMX and does not buy, sell, or trade any shares of CTMX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/